Clinical trials: Neuron Disease, Motor
Castration-resistant Prostate Cancer, Metastatic Cancer
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
- Trial name
- NCT04090528
- Testing
- pTVG-HP, pTVG-AR, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
This is a Phase 1, single-center study conducted in 2 parts: Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts.
- Trial name
- NCT05795907
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sanofi
Neuromuscular Disease, Motor Neuron Disease
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
Background: Electrical impedance myography (EIM) is a new technique being studied to see if it is helpful in evaluating muscle disorders and nerve disorders.
- Conditions
- Neuromuscular Disease, Motor Neuron Disease, Inherited Neuromuscular Conditions, Inherited Neuropathies
- Trial name
- NCT01900132
- Testing
- EIM testing, Nerve & muscle ultrasonography, Nerve conduction studies
- Where
- United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis (ALS)
A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV
This is a prospective, open-label, follow up study to protocol 101/2 - continued treatment by IPL344 IV administered once a day in up to 15 participants with ALS.
- Trial name
- NCT03755167
- Testing
- IPL344
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Immunity Pharma Ltd.
Amyotrophic Lateral Sclerosis
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS)
A Not for Profit Phase II Study to Evaluate Safety, Efficacy and Biomarkers secondary endpoints of Human Neural Stem cell intracerebroventricular transplantation in amyotrophic lateral sclerosis patients: a randomized, placebo…
- Trial name
- STEMALS (NCT06344260)
- Testing
- human Neural Stem Cells (hNSC)
- Where
- 4 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Amyotrophic Lateral Sclerosis
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
- Trial name
- NCT06266403
- Testing
- Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Penn State University
BRCA1 Mutation, High-grade Serous Ovarian Cancer
Breast Cancer BRCA1 Carriers: a Pilot Study
The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates…
- Conditions
- BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05062174
- Testing
- Mifepristone 200 MG, Prophylactic mastectomy
- Where
- 2 sites in United States
- Sponsor
- Indiana University
Amyotrophic Lateral Sclerosis, Nervous System Diseases
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique…
- Conditions
- Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease
- Trial name
- NCT01495390
- Where
- 6 sites in United States
- Volunteers
- 139 people
- Sponsor
- Massachusetts General Hospital
Spinal Muscular Atrophy (SMA)
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it.
- Trial name
- Sparkle (NCT07287982)
- Testing
- ARGX-119 IV
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 60 people
- Sponsor
- argenx
Alzheimer Disease, Amyotrophic Lateral Sclerosis
The Ontario Neurodegenerative Disease Research Initiative
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a province-wide collaboration studying dementia and how to improve the diagnosis and treatment of neurodegenerative diseases including: Alzheimer's disease (AD)…
- Conditions
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson Disease
- Trial name
- ONDRI (NCT04104373)
- Testing
- Observational Cohort
- Where
- 12 sites in Canada
- Volunteers
- 522 people
- Sponsor
- Ontario Neurodegeneration Disease Research Initiative
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
Part 1: This is an open label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between Treatment A and Treatment B for Part 1), study part to determine the relative…
- Trial name
- NCT05797701
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.
- Trial name
- NCT05673109
- Testing
- AC176
- Where
- 5 sites in China
- Volunteers
- 8 people
- Sponsor
- Accutar Biotechnology Inc
Amyotrophic Lateral Sclerosis, ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support.
- Trial name
- NCT03324399
- Testing
- probiotic
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Amyotrophic Lateral Sclerosis
Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)
Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.
- Trial name
- NCT01933321
- Testing
- Intrathecal autologous stem cell
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Validation Of Tidal/End -Tidal CO2 in ALS
The study team propose that a new, hand-held test device may be valuable in the management of breathing failure in patients with Motor Neurone Disease (MND).
- Trial name
- VOTECO2ALS (NCT03764384)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Amyotrophic Lateral Sclerosis, Dietary Habits
Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)
The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients complemented by the analysis of fatty acid distribution in erythrocyte lipids.
- Conditions
- Amyotrophic Lateral Sclerosis, Dietary Habits, Disorder of Fatty Acid Metabolism
- Trial name
- JERN_ALS (NCT02572479)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Jena
Amyotrophic Lateral Sclerosis
A Study of IPL344 in the Treatment of ALS Patients
This is a prospective, open-label, phase 1/2a study, dose escalation, to evaluate tolerability, safety, and PK of I.V. administered IPL344 in participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- ALS (NCT03652805)
- Testing
- IPL344
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Immunity Pharma Ltd.
Muscular Atrophy, Spinal
Natural History of SMA
This is an investigator initiated observational study with the aim to record several aspects of function, care and adverse events in a large cohort of SMA patients followed longitudinally by using a structured academic disease…
- Trial name
- iSMAR (NCT05755451)
- Where
- 5 sites in Italy
- Volunteers
- 1,200 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Amyotrophic Lateral Sclerosis
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin).
- Trial name
- NCT03068754
- Testing
- Acthar
- Where
- 69 sites in United States, Argentina and 5 more
- Volunteers
- 143 people
- Sponsor
- Mallinckrodt
Amyotrophic Lateral Sclerosis, Charcot Disease
Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.
This is proof-of-concept, single-arm, single-center study to assess the safety and explore the efficacy of repeated US transient disruptions of the blood-brain barrier (BBB) in Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- Son-ALS (NCT07571486)
- Testing
- SonoCloud-4 (SC4) device
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.